Exome Asset Management’s VYNE Therapeutics VYNE Stock Holding History

Exome Asset Management’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-208,970	Closed	-$345K	–	97
2025 Q2	$345K	Sell	208,970 -253,831	-55%	-$330K	0.26%	55
2025 Q1	$731K	Buy	462,801 +109,367	+31%	+$269K	0.65%	43
2024 Q4	$1.18M	Hold	353,434	–	–	0.89%	42
2024 Q3	$664K	Hold	353,434	–	–	0.45%	52
2024 Q2	$696K	Sell	353,434 -62,000	-15%	-$155K	0.62%	43
2024 Q1	$1.28M	Buy	415,434 +297,334	+252%	+$641K	1.09%	42
2023 Q4	$275K	Buy	+118,100	New	+$368K	0.27%	50

Other funds holding VYNE

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Exome Asset Management's VYNE Position: Q3 2025 in Review

Exome Asset Management sold out of VYNE Therapeutics (VYNE) in Q3 2025, closing a stake of 208,970 shares — an estimated $345K sold.

Exome Asset Management first reported a position in VYNE in Q4 2023 and held it in 7 quarters. The position peaked at $1.28M in Q1 2024. 36 funds tracked by Wall St. Rank hold VYNE as of Q3 2025.

Exome Asset Management reported no remaining VYNE Therapeutics position as of Q3 2025 after selling out during the quarter.
Exome Asset Management sold 208,970 VYNE Therapeutics shares in Q3 2025, an estimated $345K.
Exome Asset Management first reported a position in VYNE Therapeutics in Q4 2023 and held it in 7 quarters.
Exome Asset Management's VYNE Therapeutics position peaked at $1.28M in Q1 2024.
36 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q3 2025.

Based on Exome Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.